Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.

Michele Schiavon Roberto VisentinBritta GöbelMichela RizClaudio CobelliThomas KlabundeChiara Dalla Man

Published in: Diabetes, obesity & metabolism (2021)

SAR425899 and liraglutide improved postprandial glucose control in overweight to obese subjects with T2D. A significantly higher enhancement in beta-cell function was shown by SAR425899 than liraglutide.

Keyphrases

type diabetes
blood glucose
weight loss
glycemic control
metabolic syndrome
adipose tissue
cardiovascular disease
physical activity
body mass index
obese patients
clinical evaluation